NCT02985333

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.

Detailed description

Treatment for relapsed/refractory multiple myeloma (MM)remains a crucial challenge.The investigators have previously shown that the combination of paclitaxel and cyclophosphamide acts synergistically to induce apoptosis of myeloma cells in vitro. Based on these preclinical studies, the investigators initiated a phase II clinical trial of paclitaxel 175 mg/m(2) IV over 3 h d1 combined with cyclophosphamide 200 mg/m(2) IV over 30-60 min d1,3,5 and dexamethasone 20mg IV over 30-60 min d1-4 in patients with relapsed or refractory MM. This regimen was administered every four weeks for a total of six cycles

Conditions

• Relapse/Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Paclitaxel	Paclitaxel 170 mg/m(2) IV over 3 h d1
DRUG	Cyclophosphamide	Cyclophosphamide 200mgmg/m(2) IV d1,3,5
DRUG	Dexamethasone	Dexamethasone 20mg iv d1-4

Timeline

• Start date: 2014-01-01
• Primary completion: 2018-12-01
• Completion: 2019-06-01
• First posted: 2016-12-07
• Last updated: 2018-05-14

Locations

1 site across 1 country: China